At meeting held on 04 November 2015
J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 04 November 2015, has approved the acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories, South Africa (Biotech), held by Africa Biopharma Investments by a company's subsidiary, subject to necessary approvals and definitive agreements to be entered into with the seller.The Company's subsidiary J.B. Healthcare presently holds 21,07,990 (49%) ordinary shares in Biotech, besides 175,591 Non-Redeemable Convertible Preference Shares. Post the proposed acquisition, conversion of preference shares and certain fresh issuance of ordinary shares by Biotech, the shareholding of the company's subsidiaries in Biotech will increase to over 95%.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app